- Oral presentation
- Open Access
Hand eczema and other inflammatory skin diseases: efficacy of oral alitretinoin
© Boni et al; licensee BioMed Central Ltd. 2015
- Published: 11 March 2015
- Atopic Dermatitis
- Lichen Planus
- Skin Inflammatory Disease
Alitretinoin is a vitamin A derivative. It’s a pan-agonist of Retinoic Acid Receptors and Retinoid X Receptors. It interferes with keratinocytes’ proliferation and differentiation and exerts immunomodulatory and anti-inflammatory activity. Its clinical efficacy in the treatment of chronic hand eczema is well demonstrated. Recently, various case reports and case series pointed out its efficacy in other skin inflammatory disorders such as atopic dermatitis, psoriasis, lichen planus, Darier’s disease, Hailey Hailey’s disease, lichen simplex, pityriasis rubra pilaris and cutaneous lupus erythematosus.
We assessed the efficacy of oral alitretinoin in hand eczema and in other inflammatory skin disorders with palmar and extra-palmar localization. In the last 2 years, 41 patients received oral alitretinoin for the treatment of severe chronic hand eczema. 24 of them exclusively suffered of eczema with palmar localization. On the other side, 17 showed different clinical manifestations involving hands and other skin areas: nine with palmo-plantar eczema; two with eczema of the hands, feet and limbs; one had widespread hyperkeratotic eczema; one patient with severe atopic dermatitis and another one with nummular eczema; three patients suffered of psoriasis of the feet and/or hands.
36 patients received treatment for at least 3 months and up to 9 month. In 72.2% of them, remission of hand eczema was observed, evaluated as clear or almost clear hands according to “Physician Global Assessment” score. The median time to relapse was 6.4 months after discontinuation of treatment. Clinical response or improvement was also observed in patients suffering of eczema of the feet, widespread eczema, atopic dermatitis and psoriasis.
This study provides evidence that oral alitretinoin is effective in hand eczema. We confirm oral alitretinoin as desirable treatment in chronic hand eczema due to its anti-inflammatory activity and safety profile without altering skin barrier function. Moreover, its shorter half-life makes it a preferable treatment in women in childbearing age compared with other retinoids. Our data also showed its efficacy in other skin inflammatory diseases, as previously reported in the literature. Further studies will have to support its use in other skin inflammatory diseases with palmar and extra-palmar localization.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.